Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Kent Mouw MD, PhD

Kent W. Mouw MD, PhD

Co-Director, Bladder Cancer Center, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts

Disclosures

Disclosures reported

Honoraria:  UpToDate, OncLive

Consulting:  Pfizer, EMD Serono

Recent Contributions to PracticeUpdate:

  1. Outcomes With Pembrolizumab in Patients Previously Treated With Chemoradiation or Total Cystectomy
  2. Effects of Berzosertib With Cisplatin and Gemcitabine in Advanced Urothelial Carcinoma
  3. Hypofractionated Radiotherapy in Locally Advanced Bladder Cancer
  4. Upper Tract Urothelial Cell Carcinoma: Part 2
  5. Genitourinary Tumor Board: Bladder Cancer

Elsewhere

Most Read This Week

Recently Updated